Patterns of Interstitial Lung Disease in Egyptian Patients with Systemic Sclerosis: Relation to Disease Parameters

被引:2
|
作者
Abdelati, Abeer Ali [1 ]
Deghady, Akram Abd-Elmonaem [2 ]
Abdelhady, Ahmed Mohamed [3 ]
Bastawy, Rim Aly [4 ]
Shaaban, Ahmed [1 ]
机构
[1] Alexandria Univ, Fac Med, Dept Internal Med, Rheumatol & Clin Immunol Unit, Alexandria, Egypt
[2] Alexandria Univ, Fac Med, Dept Clin & Chem Pathol, Alexandria, Egypt
[3] Alexandria Univ, Fac Med, Chest Dept, Alexandria, Egypt
[4] Alexandria Univ, Fac Med, Dept Radiodiag, Alexandria, Egypt
关键词
Systemic sclerosis; interstitial; HRCT; interleukin-33; pneumonia; pleuroparenchymal fibroelastosis; SCLERODERMA; MANIFESTATIONS; CLASSIFICATION; PNEUMONIA; CYTOKINE; TRIALS; IL-33; CELL;
D O I
10.2174/1573397118666220818095927
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Pulmonary involvement is the most common leading cause of morbidity and mortality associated with systemic sclerosis. Therefore, identifying the various patterns of pulmonary affection is crucial in the clinical management of these patients. In the current study, we aim to investigate the patterns of interstitial lung disease (ILD) associated with SSc patients (SSc-ILD) and their relation to serologic markers and clinical parameters. Methods A cross-sectional study was undertaken on thirty-four adult SSc patients who met the 2013 ACR/EULAR criteria for SSc and Forty healthy controls of matched age and sex. The patients were subjected to history taking, clinical examination, skin assessment using the modified Rodnan Skin Score (mRSS), chest x-ray (CXR), pulmonary function test (PFTs), and high resolution computed tomography of the chest (HRCT). Routine laboratory tests were conducted in addition to immunologic tests and an enzyme-linked immunosorbent assay (ELISA) to determine the IL-33 level. Results ILD was found in 23 SSc patients (67.6%); 20 patients had diffuse type while 3 patients had limited type. Non-specific interstitial pneumonia (NSIP) was found in 56.5%, usual interstitial pneumonia (UIP) was found in 21.7%, pleuroparenchymal fibroelastosis (PPFE) was found in 8.7%, and organizing pneumonia (OP) with the mixed pattern was found in 13% of SSc patients. Additionally, the mean IL-33 level in SSc patients was 98 +/- 12.7 compared to 66.2 +/- 10.6 in the control group (p < 0.001), with ILD patients having a significantly higher level (101.7 +/- 13.4) than those without (90.4 +/- 6.2), and a strong positive correlation with mRSS. Conclusion Even in asymptomatic patients with SSc, ILD is prevalent, with NSIP being the most common pattern. IL-33 could be considered a potential biomarker for predicting the presence of ILD in SSc patients.
引用
收藏
页码:189 / 196
页数:8
相关论文
共 50 条
  • [41] Interstitial lung disease in systemic sclerosis: current and future treatment
    Giacomelli, Roberto
    Liakouli, Vasiliki
    Berardicurti, Onorina
    Ruscitti, Piero
    Di Benedetto, Paola
    Carubbi, Francesco
    Guggino, Giuliana
    Di Bartolomeo, Salvatore
    Ciccia, Francesco
    Triolo, Giovanni
    Cipriani, Paola
    RHEUMATOLOGY INTERNATIONAL, 2017, 37 (06) : 853 - 863
  • [42] Treatment of systemic sclerosis-associated interstitial lung disease
    Prasse, A.
    Bonella, F.
    Mueller-Ladner, U.
    Witte, T.
    Hunzelmann, N.
    Distler, J.
    ZEITSCHRIFT FUR RHEUMATOLOGIE, 2020, 79 (03): : 294 - 303
  • [43] Systemic Sclerosis Associated Interstitial Lung Disease: A Comprehensive Overview
    Mackintosh, John A.
    Stainer, Anna
    Barnett, Joseph L.
    Renzoni, Elisabetta A.
    SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE, 2019, 40 (02) : 208 - 226
  • [44] Management of systemic sclerosis-associated interstitial lung disease
    Roofeh, David
    Jaafar, Sara
    Vummidi, Dharshan
    Khanna, Dinesh
    CURRENT OPINION IN RHEUMATOLOGY, 2019, 31 (03) : 241 - 249
  • [45] Relevance of immunomodulatory therapy for interstitial lung disease in systemic sclerosis
    Aringer, Martin
    Riemekasten, Gabriela
    BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY, 2021, 35 (03):
  • [46] Genetic Susceptibility to Interstitial Lung Disease Associated with Systemic Sclerosis
    Tochimoto, Akiko
    Kawaguchi, Yasushi
    Yamanaka, Hisashi
    CLINICAL MEDICINE INSIGHTS-CIRCULATORY RESPIRATORY AND PULMONARY MEDICINE, 2015, 9 : 135 - 140
  • [47] Interstitial lung disease in systemic sclerosis: current and future treatment
    Roberto Giacomelli
    Vasiliki Liakouli
    Onorina Berardicurti
    Piero Ruscitti
    Paola Di Benedetto
    Francesco Carubbi
    Giuliana Guggino
    Salvatore Di Bartolomeo
    Francesco Ciccia
    Giovanni Triolo
    Paola Cipriani
    Rheumatology International, 2017, 37 : 853 - 863
  • [48] Functional Disability among Systemic Sclerosis Patients: Relation to Disease Characteristics and Quality of Life Parameters
    Zaghlol, Rabab S.
    Dawa, Ghada A.
    Makarm, Wafaa K.
    CURRENT RHEUMATOLOGY REVIEWS, 2022, 18 (03) : 257 - 265
  • [49] Detection, screening, and classification of interstitial lung disease in patients with systemic sclerosis
    Hoffmann-Vold, Anna-Maria
    Molberg, Oyvind
    CURRENT OPINION IN RHEUMATOLOGY, 2020, 32 (06) : 497 - 504
  • [50] Interstitial Lung Disease in Systemic Sclerosis: A Single-center Retrospective Analysis
    Yayla, Mucteba Enes
    Balci, Gulsah
    Torgutalp, Murat
    Eroglu, Didem Sahin
    Dincer, Ayse Bahar Kelesoglu
    Guloksuz, Emine Gozde Aydemir
    Sezer, Serdar
    Yuksel, Mehmet Levent
    Ates, Askin
    Turgay, Tahsin Murat
    Kinikli, Gulay
    CURRENT RHEUMATOLOGY REVIEWS, 2022, 18 (02) : 150 - 156